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Abstract
Background. Early and long-term use of cyclosporine A
(CsA) leads to increased risks of renal toxicity. We hypoth-
esized that administration of daclizumab in combination
with mycophenolate mofetil (MMF) allows a relevant re-
duction in the dose of CsA.
Methods.Wecarried out a 3-year, prospective, randomized,
controlled clinical multi-centre trial in 156 patients. The pa-
tients were randomized to standard treatment (CsA, MMF,
steroids) or to high-dose daclizumab (first dose: 2 mg/kg),
in combination with low-dose CsA, MMF and steroids. We
maintained the mean CsA levels of daclizumab patients at
57% of standard patients (132 versus 216 ng/ml) on Day 7
post-transplant, and 84% by 6 months.
Results. Primary outcome, creatinine clearance (with im-
putation of informative dropouts) at 12 months, was signif-
icantly better in daclizumab-treated (34± 17) than standard
patients (29 ± 17; P = 0.028, two sided). Only 5 cases of
BPAR were recorded in the daclizumab compared to 22 in
the standard group (P = 0.0016). Daclizumab patients had
91% event-free survival after 1 year compared to 66% in
standard patients (P = 0.00017).
Conclusion. We demonstrate here that high-dose da-
clizumab in combination with lower CsA levels in adult
renal transplant recipients is as or more effective than stan-
dard regimen (CsA,MMF, steroids) and may result in better
outcomes at 12 months post-transplant with no increase in
adverse reactions.
Keywords: cyclosporine; daclizumab; immunosuppression; kidney;
transplantation
Introduction
Cyclosporine A (CsA) and tacrolimus, which prevent T-
lymphocyte activation by calcineurin inhibition (CNI), are
currently the anchor medication of most immunosuppres-
sive regimens in kidney transplant recipients [1]. However,
there are many efforts to reduce or even withdraw CNIs as
their early and long-term administration is associated with
a high risk of developing renal complications as well as
other adverse side effects such as hypertension, hyperlip-
idaemia or diabetes mellitus. Virtually all patients treated
with CNIs develop nephrotoxicity [2], and a reduction in the
use of CNIs could therefore result in a therapeutic benefit.
Standard immunosuppression usually consists of a triple
drug therapy of three drug classes: CNIs, anti-proliferative
agents including mycophenolate mofetil (MMF) and corti-
costeroids. As CNIs act against T-cell activation [3], MMF
inhibits T- and B-cell proliferation [4], which is of addi-
tional benefit because recent data increase the importance
of B cells in graft dysfunction and rejection processes [5,6].
The humanized monoclonal antibody daclizumab compet-
itively binds to the CD25 subunit of the IL-2 receptor fur-
ther inhibiting the activation of T cells. The introduction of
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Table 1. Medication regimen in the early post-operative period for standard therapy patients and daclizumab patients
Medication Standard group Daclizumab group
Early post-operative period (<6 months)
Daclizumab 1st dose, day 0 – 2 mg/kg
2nd–5th dose; day 14, 28, 42, 56 – 1 mg/kg
Mycophenolate mofetil 2 × 1 g/day 2 × 1 g/day
Steroids (tapering) Min. dose 7.5 mg/day Min. dose 7.5 mg/day
Cyclosporine (trough level) 150–250 ng/ml 75–125 ng/ml
Reaching at 6 months 125–175 ng/ml 50–75 ng/ml
Month 7–12
Mycophenolate mofetil 2 × 1 g/day 2 × 1 g/day
Steroids (tapering) Min. dose 5 mg/day Min. dose 5 mg/day
Cyclosporine (trough level) 125–175 ng/ml 50–100 ng/ml
Reaching at 12 months 100–150 ng/ml 50–75 ng/ml
induction therapies with non-depleting antibodies, such as
daclizumab, as a supplement to standard immunosuppres-
sion has resulted in further achievements in the reduc-
tion of acute rejection [7,8] without increasing the risk for
infection.
As it is clear that induction therapies with anti-CD25 an-
tibodies, such as daclizumab, decrease rejection episodes
in combination with standard therapy [7,9], it has been hy-
pothesized that the administration of daclizumab can allow
a reduction in the dose of CNIs. However, complete avoid-
ance of cyclosporine in de novo kidney transplant patients
has resulted in increased rejection rates [10,11]. These con-
siderations have led to the current trial design, in which
a decreased dose of cyclosporine is administered to pa-
tients receiving daclizumab in combination with MMF and
steroids with the reasoning that this could be sufficient to
provide effective rejection prophylaxis. Decreased expo-
sure to CNIs may result in a reduction in nephrotoxicity
but may carry an increased risk for rejection. Over the last
years, two large clinical trials (‘CAESAR’ with 536 pa-
tients and ‘SYMPHONY’ with 1645 patients) [12,13] were
published that tested this hypothesis and found no improve-
ment in renal function between daclizumab with low- and
standard-dose CsA without daclizumab. Interestingly, both
treatment arms had similar rejection rates despite the use
of daclizumab, which raises the question of optimal CsA
exposure in combination with anti-CD25 antibodies [14].
In these two studies, CsA trough levels in the daclizumab
plus low CsA group were set to between 50 and 100 ng/ml,
while higher CsA levels between 120 and 130 ng/ml may
provide a better balance between rejection prophylaxis and
nephrotoxicity. In order to provide more information on
the optimal dosing of CsA, we present here the results of
a 3-year, prospective, randomized trial investigating renal
function, efficacy and safety of daclizumab, MMF, steroids
and low-dose CsA in comparison to standard therapy in
adult renal transplant recipients.
Patients and methods
Patients and study design
This investigator-initiated trial was a prospective, randomized, controlled,
multi-centre study conducted in 14 centres in Germany, Switzerland and
Austria. Patients were recruited between December 2000 and February
2003 and data collected until February 2006. This trial was performed
in accordance with ICH/GCP guidelines and the amended Declaration
of Helsinki following approval from the Institutional Review Committee
at each centre. Informed consent was obtained from each patient before
enrolment.
Adult (>18 years) primary renal allograft recipients, whose graft was
obtained from a deceased donor, were eligible for enrolment. The most
important exclusion criteria were cold-ischaemia time >30 h, combined
or prior transplants, grafts from living donors and the use of another in-
duction agent. Other factors that precluded participation were white-blood
count<2.5 × 109/l, platelet count<100 × 109/l or haemoglobin<60 g/l.
The patients were required to have panel reactive antibodies (current or
peak) <20%. Eligible patients were enrolled prior to transplantation and
randomized centrally by telephone after stratification by centre and age
(< or≥60 years). Randomization was carried out in a 1:1 manner to either
standard therapy or to the experimental group consisting of daclizumab
induction and low-dose CsA (Table 1) using computer-generated random-
ization lists. After verification through the central office, centres were
notified by fax. The patients enrolled in the study were treated according
to the protocol for 1 year. After this active treatment period, the patients
were followed for another 2 years for selected parameters as defined in the
study protocol allowing evaluation of long-term efficacy, safety and graft
survival. Studymonitoringwas carried out centrally. Data were recorded in
a computer database system and cross-checked by computer with central
data verification and monitoring.
Immunosuppression
Both immunosuppressive regimens are summarized in Table 1. Patients
with standard therapy received CsA, MMF and steroids without da-
clizumab. The initial CsA starting dose in this group was 10 mg/kg admin-
istered within 6 h after transplantation; thereafter, CsA doses were targeted
to achieve trough levels between 150 and 250 ng/ml initially (as per centre
practice) with a gradual decrease to reach 125–175 ng/ml at 6 months
and 100–150 ng/ml at 12 months. The experimental group received da-
clizumab (Zenapax R©, Roche Pharma AG) induction with 2 mg/kg IV
within 24 h pre-transplant, followed by four additional IV doses of 1
mg/kg daclizumab every 2 weeks. CsA reduction was intended to reach
50% of trough levels of the standard group with a gradual taper (Table 1).
Both groups received standard therapy with MMF (2 × 1 g/day orally)
and corticosteroids as per centre practice with a minimum of 7.5 mg/day
in the first 6 months and a minimum dose of 5 mg/day in months 7–12
(Table 1) with the attempt to obtain similar doses in both groups.
Primary and secondary outcomes
Data from patients who had 12 months of follow-up, or left the trial within
these 12months were analysed for the primary endpoint calculation. Renal
function 12 months after kidney transplantation determined by creatinine
clearance (Cockcroft–Gault formula [15,16]) was the primary endpoint.
Importantly, for patients without adequate measurements at 12 months
(e.g. graft loss, death), a creatinine clearance of 0 ml/min was imputed.
Secondary endpoints included patient and graft survival at 6 and
12months, incidence of biopsy-proven graft rejection within the 12-month
follow-up, incidence of treated, OKT3/ATG (muromonab/anti-thymocyte
globulin) treated and steroid-resistant acute rejection, renal function [with
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Fig. 1. Flow chart of patients in the trial. Premature withdrawals are
further detailed in Table 4 alongwith exact breakdown of graft dysfunction
per group.
and without imputation of missing values according to the last-observed-
value-carried-forward (LOCF) method], blood pressure and lipid values.
All acute rejections were asked to be biopsy proven and defined accord-
ing to Banff 97 criteria [16]. High-dose steroids were first-line therapy
of acute rejection, depleting antibodies (OKT3/ATG), or tacrolimus could
be given in the case of severe rejection; these patients, however, had to be
removed from the trial. Adverse events were graded according to the NCI
Common Toxicity Criteria. All infections were recorded, and a subset of
infections including CMV, EBV, Herpes zoster and Herpes simplex were
specifically tracked. Delayed graft function was defined as the need for
dialysis in the first week.
Statistical analysis
In order to detect a clinically relevant difference in the creatinine clearance
of 10 ml/min (with a standard deviation of 20 ml/min) after 12 months, as
the primary endpoint of the study, with a type I error of 0.05 and a power of
80% using a two-sided t-test, 64 patients were required per randomization
arm. Patients without adequate measurement at 12 months as a conse-
quence of death or graft loss were anticipated. In order to account for these
informative dropouts in an intention-to-treat (ITT) analysis, the primary
endpoint definition was prospectively extended to a composite criterion,
assigning an artificial ‘worst possible creatinine clearance’ to cases with
graft loss or permanent graft failure within the first year. To allow for this
from a statistical point of view, a distribution-free test procedure, i.e. the
Wilcoxon rank-sum test, was planned, as creatinine clearance under this
assumption was not anticipated to be normally distributed. Accounting for
up to 10% loss of power by the application of the non-parametric test and,
in addition, taking into consideration a 10% uninformative dropout rate, a
total of 155 patients were recruited.
In addition to standard methods of descriptive analysis, the Wilcoxon
rank-sum test was used to compare groups with respect to creatinine,
or other laboratory values. As a consequence of the composite endpoint
approach described above, non-ITT-based means or medians could be
derived for these parameters. Event-related data such as time to rejection or
graft dysfunction were analysed according to the Kaplan–Meier technique
[17] and compared with the log rank test [18]. For differences in adverse
effects, Fisher’s exact test or an exact version of the chi-square test for
trend was applied.
All analyses were carried out according to ITT that was defined as the
population that included all transplanted patients with a valid randomiza-
tion, and at least one post-transplant assessment available.
Results
Patient demographics
A total of 156 patients were included in the trial; how-
ever, three of these patients were withdrawn from the anal-
ysis because they were not transplanted: two who were not
transplanted due to the bad quality of the donor kidney and
one patient who died before the transplant procedure was
completed due to a cardiovascular event (Figure 1). From
5 out of 153 patients, no post-transplant assessments were
available, and therefore, according to the pre-specified pro-
tocol, those 5 patients had to be excluded from any further
ITT analysis; in consequence, the predefined ITT popula-
tion consisted only of 148 patients, with 75 patients in the
daclizumab and 73 patients in the standard therapy group.
This trial included an additional 2 years’ follow-up period
as specified by the protocol. Eleven patients were lost to
follow-up after the first 12 months of the core study period.
There were no significant differences in demographic
data between the two groups at the time of enrolment
(Table 2). The mean age (range) was 52 years (19–73 years)
for daclizumab patients and 54 (19–70 years) for standard
Table 2. Baseline patient demographics and transplant characteristics
Daclizumab Standard
Demographics (n = 148) (n = 75) (n = 73)
Gender male (%) 47 (64%) 42 (60%)
Mean age ± SD 52.3 ± 13.8 54.2 ± 12.3
Median age (range) 55 (19–73) 58 (19–70)
BMI median (range) 23.3 (17.9–36.7) 25.3 (17.1–33.1)
Neg. CMV IgG (%) 24 (34%) 25 (35%)
Patients with delayed graft
function in first week
20 20
Donor status
Donor age <60 66% 66%
Donor age ≥60 34% 34%
Median cold ischaemia in
min.a
939 (210–2070) 900 (154–1849)
Primary diagnosis leading to
transplantation
Glomerulonephritis 24 17
Nephritis 13 18
Polycystic kidney 8 14
Diabetes mellitus (type I + II) 6 4
Hypertension 7 4
Other (unknown) 17 16
Patients enrolled in the trial were equally distributed to standard therapy
and daclizumab groups in regards to gender, age and other transplant
relevant factors.
CMV, cytomegalovirus; BMI, body mass index; IgG, immunoglobulin G.
aTwo patients with a cold ischaemic time >30 h, (one patient in each
group) represent protocol violations, which, however, were included in the
ITT analysis.
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therapy patients with a high proportion (>34%) of elderly
donors ≥60 years.
During the first year post-transplant, a total of 58 pa-
tients were withdrawn from the study: 22 of the daclizumab
patients (22/75, 29%) and 36 of the standard therapy pa-
tients (36/73, 49%). Reasons for withdrawal are listed
in Figure 1, and included adverse events, rejection (see
Table 3 for breakdown), withdrawal of consent and infec-
tion. There were seven graft losses in the first 12 months
in the standard group and two in the daclizumab group
(Table 3).
Immunosuppression
The goal was a 50% reduction of CsA trough levels in the
daclizumab group. After 1 week post-transplant, the mean
CsA levels of daclizumab patients were maintained at 57%
of standard patients [132 versus 216 ng/ml on Day 7 (P <
0.0001; Figure 2)]. The levels of CsA in the daclizumab
group only slowly and gradually decreased after transplan-
tation, while the levels in the standard group were tapered
more rapidly. By the end of Month 6, the mean CsA levels
in daclizumab patients were maintained at 84% of standard
therapy patients until the end of the first year (P = 0.018
Fisher’s exact test, two-sided) and continued to remain 10–
20% lower than in the control arm.
At Month 12, the dose of MMF in both groups ranged
from 500 to 2000 mg/day. Both in the daclizumab group
(n = 46) and in the standard therapy group (n = 39), the
average daily MMF dose was 1.7 g/day. The daily dose of
corticosteroids (prednisolone equivalent) at 12 months in
the daclizumab group (n = 47) ranged from 2 to 12.5 mg,
with an average value of 5.5 mg. In the standard therapy
group (n = 38), corticosteroids ranged from 2 to 15 mg,
with an average value of 6.5 mg/day.
Primary endpoint: renal function
The primary endpoint renal function at 12 months (with
imputation of ‘0’ for informative dropouts), determined by
mean calculated creatinine clearance according to the proto-
col, was significantly better in daclizumab-treated patients
compared to standard therapy patients [34.1 ± 17.4 ml/
min in daclizumab patients (n= 74) versus 29.4± 16.5 ml/
min in standard therapy patients (n = 71; P = 0.028, two
sided; Table 3)]. It is important to note that this combined
analysis included all patientswhere graft failures and deaths
were assigned the lowest rank, thereby providing a more
comprehensive view on post-transplant outcome.
In order to provide better insight in the actual renal func-
tion of both groups, we calculated themeanGFR (according
to the Cockcroft–Gault formula) with and without impu-
tation of missing values. The observed calculated creati-
nine clearance at 12 months (without any imputation) was
∼7ml/min better in the daclizumab group without reaching
statistical significance (Table 3). Similar results were ob-
tained when missing values were imputed (LOCF method)
demonstrating better renal function over the 3-year period
for the daclizumab group, reaching statistical significance
only between Day 14 and Month 3 as well as on Month 9
(Figure 3A).
Similarly, the Wilcoxon rank-sum test results show sig-
nificance at 12 months in favour of daclizumab patients
with respect to creatinine (P = 0.014, two sided, Table 3),
when graft failures and deaths were assigned the lowest
rank. In order to provide a complete picture of renal function
parameters, the time course of observed serum creatinine
(without any imputations) is shown in Figure 3B. Themean-
observed serum creatinine concentrations over the 3-year
period were always better in the daclizumab group already
beginning at 2 weeks post-transplant reaching statistical
significance at various time points after transplantation. At
36 months, the mean creatinine value in the daclizumab pa-
tients (n = 43) was 1.7 mg/dl, while in the standard therapy
patients (n = 36), the mean concentration was 2.1 mg/dl
(P = 0.048).
Acute rejection
The incidence of and time to first biopsy-proven acute re-
jection (BPAR) (Figure 4A) within the first 12 months as
shown on the Kaplan–Meier plot demonstrates a highly sig-
nificant difference (P < 0.002, two sided for both param-
eters) between the two groups. Within the first 12 months,
only 5/75 daclizumab patients (6.6%) experienced BPAR
compared to 19/73 patients (26%) in the standard group
(P = 0.0016). Three of the 19 standard therapy patients
had two BPAR for a total of 22 events in the standard ther-
apy group (Table 4). Furthermore, daclizumab patients also
had less severe rejections with less antibody use (n= 4 ver-
sus n = 10) for severe or steroid refractory rejections than
standard therapy patients. In addition, eight patients in the
standard therapy group were converted to tacrolimus due to
rejection compared to only four patients in the daclizumab
group. Considering a composite endpoint of graft loss or
BPAR likewise, daclizumab patients had 91% event-free
survival after 1 year, while standard therapy patients had
66% event-free survival (P = 0.00017). This represents an
almost 4-fold lower risk of rejection or graft loss in the
daclizumab group.
Patients with rejection in both groups had significantly
worse renal function (Figure 3C) beginning on Week 6.
Even patients with borderline rejections had compromised
renal function (39.8 ± 16.3 ml/min; P < 0.05, Wilcoxon
test, n = 6) at 1 year compared to rejection-free patients.
In order to further differentiate the effect of better re-
jection prophylaxis from lower CsA levels on renal func-
tion, we performed a post hoc analysis comparing renal
function from all patients without any rejection episodes
(Figure 3D). In these rejection-free patients, differences be-
tween both groups were smaller and did not reach statistical
significance.
Within the first year in the daclizumab group, no biopsy-
proven chronic rejection and/orCsA toxicitywere observed,
while two patients in the standard therapy groups experi-
enced biopsy-proven chronic rejection, and nine patients
had biopsy-proven cyclosporine toxicity (Table 4). In addi-
tion, in nine cases, CsA toxicity was suspected by the in-
vestigator in the standard therapy arm. Biopsies were only
administered if deemed clinically necessary, withmore (n=
43) biopsies due to renal dysfunction in the standard group
compared to the daclizumab group (n = 25). Premature
withdrawal events due to rejection in the first 12 months
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Table 3. Primary endpoint, graft survival, adverse events, infection and premature withdrawal
Daclizumab Standard
Mean creatinine clearance 12 months 34.1 ± 17.4 29.4 ± 16.5
Median with imputation of informative dropouts∗ (P = 0.028, two sided) 31.9 (n = 74) 27.8 (n = 71)
Mean creatinine clearance 12 months 57 ± 22 (n = 74) 50 ± 25 (n = 71)
Median (range) with imputation LOCF∗∗ (P = 0. 098, two sided) 53 (11–113) 50 (8–137)
Mean creatinine clearance 12 months 59 ± 21 (n = 61) 52 ± 22 (n = 53)
Median (range) only observed cases (P = 0.208, two sided) 54 (22–112) 52 (9–98)
Mean creatinine 12 months with imputation of informative dropouts∗ (P = 0.014, two sided) 1.80 ± 1.10 (n = 75) 2.60 ± 2.20 (n = 73)
Mean creatinine 12 months 1.81 ± 1.07 (n = 75) 2.35 ± 2.06 (n = 73)
Median (range) with imputation LOCF∗∗ (P = 0.058, two sided) 1.50 (0.74–5.64) 1.63 (0.64–11.3)
Mean creatinine 12 months 1.56 ± 0.66 (n = 53) 1.94 ± 1.51 (n = 42)
Median (range) only observed cases (P = 0.139, two sided) 1.44 (0.74–4.20) 1.80 (0.74–10.2)
(n = 75) (n = 73)
Patient survival at 12 months 97.3% 93.2%
Graft survival (censured for death) at 12 months 97.3% 89.7%
Patient survival at 24 months 94.6% 91.8%
Graft survival (censured for death) at 24 months 95.8% 84.6%
Patient survival at 36 months 93.3% 89.0%
Graft survival (censured for death) at 36 months 90.2% 81.6%
Premature withdrawal (12 months)
Patients with events 22 (29%) 36 (49%)
Number of events 30 65
Death 2 2
Rejection 6 17
Refractory rejection 3 7
Antibody-treated rejection 4 10
Conversion to tacrolimus due to rejection 4 8
Graft thrombosis 0 1
Adverse events 7 15
Infection 5 8
Non-functioning graft 1 3
Other 7 18
Withdrawal of informed consent 2 1
Adverse events (12 months)∗∗∗
Total adverse events: Patients with events 70 (93%) 70 (96%)
Total adverse events: Number of events 203 178
NCI grade NCI grade
2 3 4 2 3 4
Hematological (bleeding/blood) 7 4 3 8 9 2
Cardiovascular 4 4 1 0 2 3
Gastrointestinal 10 2 1 6 3 1
Metabolic 17 5 0 7 7 0
Neurological 12 4 1 9 3 1
Renal/genitourinary 10 2 2 1 7 7
Infection (12 months)
Patients with events 51 (68%) 49 (67%)
Number of events 89 74
Bacterial 40 39
Fungal 9 3
CMV 19 15
Herpes 6 11
Other viral 9 4
Unknown 6 2
∗For informative dropouts (patients who died, lost their graft or were withdrawn due to severe rejection or toxicity), an arbitrary value and worst possible
rank was assigned.
∗∗In case of missing values, the last observed value was carried forward (LOCF-method).
∗∗∗The adverse event profiles did not differ significantly from each other. None of the calculated P-values for various events indicated a statistically
significant difference between the two groups.
demonstrated a favourable trend in the daclizumab group;
there were six severe rejections in the daclizumab group
compared to 17 in the standard therapy group because of
treatment with ATG or tacrolimus (see Table 3 for more
complete data).
Safety profile: infections and lipids
The adverse event profiles of the two treatment groups
in the first 12 months did not differ significantly (Table 3).
No differences were noted in number of patients with infec-
tions between the two groups; 68% (51/75) of daclizumab
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Fig. 2. Cyclosporine trough levels from Day 7 to Day 183 in daclizumab
patients (circles) and standard therapy patients (squares).
patients experienced one or more infection episodes versus
67% (49/73) of standard therapy patients. Themost frequent
adverse occurrence was bacterial infection with 40 reports
in the daclizumab group and 39 in the standard therapy
group. Finally, there were no differences in blood pressure
and lipids between the two groups (data not shown) and no
reported malignancies in either group.
Patient and long-term graft survival
Patient survival was similar in both groups. At 12 months,
seven deaths were observed within the 148 ITT popula-
tions, with two deaths in the daclizumab group and five
deaths in the standard therapy group (Table 3). Within the
3 years of follow-up, five deaths occurred in the daclizumab
group, while eight were observed in the standard therapy
group. Additionally, five patients experienced graft loss or
permanent dialysis in the daclizumab group compared to
15 in the standard group (P = 0.035, log rank test, two-
sided; Figure 4B) over the 3-year observation period. Two
out of 5 patients with BPAR in the daclizumab group lost
their graft compared to four deaths and seven graft losses in
19 patients with rejection in the standard group.
Discussion
This prospective study demonstrates that high-dose da-
clizumab induction (2 mg/kg initial dose) in combination
with reduced CsA, steroids and MMF is a safe and effica-
cious regimen following kidney transplantation that allows
a relevant reduction in early CsA exposure within the first
12 months in an immunologically low-risk population. This
high-dose daclizumab regimen appears to be superior to
standard-dose CsA regimen in combination with MMF and
steroids with respect to graft survival, renal function and
acute rejection episodes. However, with the current study
design, we could not prove the hypothesis that a decreased
dose of CsA led to improved graft function. Patients with-
out rejection had only minor, not significant differences
in renal function despite marked differences in CsA ex-
posure, while patients with rejection clearly had inferior
renal function in a post hoc analysis suggesting that the
superior rejection prophylaxis with high-dose daclizumab
induction and sufficient CsA levels could provide a poten-
tial explanation for the better outcomes in the daclizumab
group.
A major concern regarding CNI immunosuppression is
the development of nephrotoxicity [19]. In order to mini-
mize CNI-related side effects, several attempts have been
made to reduce, withdraw or even avoid CNIs. Com-
plete CNI-free immunosuppression in the immediate post-
transplant period, however, has resulted in an unacceptably
high rejection rate of about 50% using a regimen of anti-
CD25 antibody,MMF and steroids [10]. Similarly complete
CNI withdrawal with MMF and steroids was not successful
during the first 2 years post-transplant as demonstrated in
two earlier studies [20,21] and a recent multi-centre study
[12]. In this latter trial, CNI withdrawal 6 months post-
transplant was associated with an increased risk of BPAR
compared to a low-dose CsA group (38% versus 25% at
12 months) [12]. Success in complete CNI withdrawal
has been obtained only in few studies in which CNI was
withdrawn after introduction of MMF in long-term main-
tenance patients (>3 years post-transplant), without an
increase in acute rejection but significantly better renal
function [22,23].
Taken together, these results demonstrate that a proto-
col incorporating complete early CNI withdrawal or even
complete CNI avoidance solely with anti-CD25, MMF and
steroids is not an optimal strategy. Instead, a CNIminimiza-
tion strategy could prove to be a successful alternative in
order to lower the well-known nephrotoxic effects of CNIs
[14]. High-dose anti-CD25 induction with daclizumab
(2 mg/kg initially) successfully allowed a significantly re-
duced CNI exposure while providing excellent rejection
prophylaxis. However, we have to emphasize that the par-
ticipants in this trial were at low risk and that these results
may not be applicable to higher risk groups.
Our results confirm in part the results of Vincenti,
Nashan and Ingle [7,8,24,25], and indicate significantly de-
creased acute rejection with induction therapies. Although
only a secondary outcome, the biopsy-proven rejection rate
in the daclizumab group over the 1-year observation pe-
riod was only 7% while a rate of 26% was observed in the
standard therapy group. The average rate of biopsy-proven
rejection in kidney transplant trials with standard therapy
consisting of CsA, steroids andMMF is about 25% [12,13].
Administration of high initial daclizumab doses (initial dose
was 2 mg/kg) in concert with MMF and CsA trough lev-
els between 120 and 130 ng/ml resulted in improved kid-
ney function early during the study with excellent rejection
prophylaxis, similar to those seen with anti-CD25 induc-
tion in combination with MPA, steroids and C2-monitored
full dose CsA [25]. It is, however, not possible to conclude
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Fig. 3. Evolution of renal function over the course of the study. (A) Calculated glomerular filtration rate (Cockcroft method) with the imputation of
missing values according to the last-observed-value-carried-forward (LOCF) method and (B) observed serum creatinine values. (C) Comparison of
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Fig. 4. Time to first biopsy-proven acute rejection and time to graft loss.
(A) Differences in the rates of acute rejection between daclizumab-treated
and standard therapy groups emerged during the trial; a Kaplan–Meier
plot shows the time to the first biopsy-proven acute rejection. Daclizumab
patients were therefore significantly less likely to have BPAR within the
first 12 months (P = 0.00088) as compared to standard therapy patients.
(B) Daclizumab patients demonstrated significantly less graft losses or
permanent dialysis over the long-term follow-up (P= 0.035, log rank test,
two sided).
that the decreased dose of CsA directly led to better graft
function, because our study design cannot discern between
the effect of lower CsA doses on renal function and the
effect of initial high-dose daclizumab, which might have
provided additional potent rejection prophylaxis, leading
to subsequent better long-term renal function. The latter
hypothesis was partly confirmed by our post hoc analysis,
demonstrating deleterious effects of rejection episodes on
renal function, while different CsA doses exerted only a
minor, not significant, effect on renal function in patients
without rejection. In theory, this favourable result could also
be achieved with daclizumab added to standard CsA doses
as evidenced by the excellent outcomes in the DIRECT trial
[25]. Thus, we only can conclude that this particular reg-
imen of initial high-dose daclizumab in combination with
lower CsA doses was associated with better outcome.
It is, however, important to point out that our primary
endpoint, did not only reflect renal function, but in fact was
more a composite endpoint, because we imputed a GFR of
‘0’ for informative dropouts such as graft failure or death.
Table 4. Incidence and severity of acute and chronic rejection
Daclizumab Standard
Number of patients with (n = 75) (n = 73)
Treated acute rejection within the 1st year 6 (8%) 20 (27%)
Biopsy-proven acute rejection (BPAR) 5 19
Steroid-sensitive acute rejection 2 15
Steroid-resistant acute rejection 0 3
Steroid-resistant and antibody-sensitive
acute rejection
1 1
Antibody-sensitive acute rejection 2 3
Unknown 1 1
BPAR within the first year 5 (6.6%) 19a (26%)
Borderline 0 7a
BPAR (excluding Borderline) within the first
year
5 (6.6%) 12 (16.4%)
Banff grade I 3 3
Banff grade II 0 7a
Banff grade III 2 2
Other biopsy findings
Number of biopsies 25 43
Biopsy-proven chronic rejection 0 2
Biopsy-proven CsA toxicity 0 9
aTwo patients with borderline rejection and one patient with Banff II
rejection experienced another rejection episodes, resulting in 22 rejection
episodes in 19 patients.
As a consequence, it is difficult to compare our GFR result
with other studies, where a GFR of ‘10’ was imputed [13]
or where no imputation was performed [25]. Our compre-
hensive analysis on renal function (using observed cases or
imputed values according to LOCF) failed to demonstrate
significant differences between both groups similar to other
studies [12,13]. Given the strong trend at some timepoints
and the absolute differences of 5–7ml/min, it is conceivable
that better rejection prophylaxis in combination with lower
CsA exposure contributed to the observed outcomes with
significant differences in the primary endpoint but non-
significant differences in renal function (either observed
cases or LOCF method). But as evidenced by the large
standard deviation, the current study was not adequately
powered for the analysis of such secondary endpoints.
Becausewe used a similar hypothesiswith a similar study
design, it is important to discuss the results of the Sym-
phony study and CAESAR study in context of our results
[12,13]. Very low CsA exposure with levels between 80 and
100 ng/ml in the first 6 months resulted in higher rejection
rates of∼25% in both trials [20,33]. In our trial, higher CsA
levels and higher initial daclizumab doses (2 mg/kg ini-
tially) were used; by 183 days post-transplant, CsA trough
levels in daclizumab patients achieved levels between 120
and 130 ng/ml resulting in low incidence of rejection in
the first month and virtually no rejections beyond the
second post-transplant month, which suggests that these
levels combined with full dose MMF were effective in ob-
taining excellent rejection prophylaxis even after anti-CD25
antibody was terminated. Our rejection rates were in a sim-
ilar range compared to other trials, in which anti-CD25 an-
tibodies were used in combination with MMF, steroids and
standard CsA doses [25]. In summary, this demonstrates
that initial high-dose daclizumab induction therapy in com-
bination withMMF has the potential to substantially reduce
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CsA exposure during the first 6months post-transplant with
no increase in rejection incidence and patient risk.
Other groups corroborate that the use of daclizumab not
only reduces acute rejection [26], but permits the reduction
of steroids [6,27,28] or the reduction or delayed introduc-
tion of the CNIs [24,29–33]. Similarly to our study, lower
CsA concentrations in combination with initially high-dose
daclizumab were associated with reduced acute rejection,
reduced need for biopsy and lower chronic rejection rates.
These results (admittedlywith a lower power) are in contrast
to the findings of two recent large clinical trials (‘CAESAR’
with 536 patients and ‘SYMPHONY’ with 1645 patients)
[12,13], which demonstrated no improvement in rejection
rates and renal function between low- and standard-dose
CsA. One obvious difference between these two studies
and our trial was the higher CsA levels and initial higher
daclizumab dose used in our study. Notably, CsA trough
levels in this study came to between 120 and 130 ng/ml,
while the two other studies achieved lower CsA levels be-
tween 80 and 100 ng/ml. As pointed out, this was asso-
ciated with better rejection prophylaxis, but actual renal
function as determined by serum creatinine and calculated
GFR (either observed cases or LOCF method) showed only
some small but not significant differences between groups.
Further randomized studies are needed to investigate this
difference and to determine the optimal CsA level for the
early post-transplant period.
Limitations of the study include the rather small number
of patients, the use of CsA trough level monitoring instead
of C2 monitoring and the high drop out rate. Despite the
rather small sample size, we were able to show significant
differences in the primary ‘composite’ endpoint, justifying
the assumptions of the power calculation. But as a con-
sequence, the power for secondary endpoints, e.g. graft
survival, graft function and rejection rates is limited, espe-
cially given the high number of withdrawals. Although the
rate of treatment failures is similar to other studies [12,13],
the study protocol required that patients who discontinued
treatment (e.g. experienced adverse events, or had severe
rejection necessitating antibody treatment and/or conver-
sion to tacrolimus) were to be removed from the trial,
as they had experienced an obvious treatment failure of
the initial immunosuppressive regimen. In 2000, when the
study was planned, the safety and efficacy of the experi-
mental daclizumab arm was largely unknown. Due to fear
of under-immunosuppression, initial daclizumab dose was
even doubled. In retrospect, with current knowledge on the
efficacy and safety of both regimens, such patients could
(and should) have been kept in the trial and additional safety
and efficacy parameters should have been captured.
Lastly, C2monitoringmay have prevented over- or under-
exposure in some patients that could have resulted in less
rejection and/or less toxicity, and excellent results with C2-
monitored full dose CsA in combination with anti CD25
have been reported [25,34]. But the current study was
planned before CsA C2 monitoring became popular, and
CsAC2monitoringmay also have some limitations [34,35].
Unfortunately, there is little evidence from well-designed
large prospective randomized trial to support the theoretical
benefits of CsAC2monitoring studies in de novo transplant
patients versus trough level monitoring [34], but undoubt-
edly CsA C2 monitoring with a better assessment of CsA
exposure might have resulted in better outcomes, especially
in the control group.
Additional trials indicate that daclizumab and MMF also
allows reduction in the use of tacrolimus without increased
risk for the patient [13], and this data therefore implies
that daclizumab combined with MMF may function as a
more principal therapeutic to lower CNI use in general.
Taken together, the recently published literature together
with this trial suggests the more widespread use of anti-
CD25 antibodies in combination with corticosteroids and
MMF, which allows a profound reduction of CNI dose in
low-risk patients. Such a low-dose CNI regimen could lead
to improved kidney function, less rejections and better graft
outcome.
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Abstract
Background. Impact of kidney transplantation on sur-
vival of French end-stage renal disease (ESRD) patients is
unknown.
Methods. A total of 1495 adults living in the Lorraine
region and starting renal replacement therapy from 1997
to 2003 were included. A propensity score (PS) of regis-
tration on the renal transplant waiting list was estimated.
Patient survival was studied using a time-dependent Cox
multivariate regression and a Cox model stratified by
PS tertiles. Survival of older patients (≥60 years) was
detailed.
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